• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

TABLE 185Mixed-treatment comparison – CIBIC-plus at 12–16 weeks (OC populations): results

TechnologyVs placeboProbability most effective
Effect95% CIProbability more effective than placebo
Placebo0.013
Donepezil−0.351−1.697 to 0.9340.8430.330
Galantamine−0.369−2.249 to 1.5220.7910.403
Rivastigmine−0.007−1.871 to 1.8900.5100.113
Memantine−0.072−1.958 to 1.8080.5780.142

From: Appendix 9, Mixed-treatment comparisons performed in specified measurement populations

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.